First ever biosimilar of interferon beta-1a approved in Russia
Represents Biocad's third authorized medicine for the treatment of relapsing-remitting multiple sclerosis.
The Ministry of Health (MoH) of the Russian Federation has awarded Biocad marketing authorization for its interferon beta-1a biosimilar, a version of Biogen’s Rebif that is a key component in treatment of relapsing-remitting multiple sclerosis (RRMS) and included in all international recommendations and protocols. Biocad started the development program for interferon beta-1a biosimilar in 2012 and it took almost 5 years to run all the development phases, including pre-clinical/clinical studies and registration. The new biosimilar will be available for Russian patients this year.
Biocad’s interferon beta-1a biosimilar is the only registered biosimilar of Rebif in Russia and worldwide, which was developed in accordance with EMA guidelines. It showed no statistically meaningful difference in pharmacokinetics and pharmacodynamics parameters during Phase I study and proved safety and efficacy equivalence to reference medicine in Phase III study.
Included in the federal list of essential drugs and special reimbursement program for medicines used in rare debilitating diseases, interferon beta-1a is one of the most demanded therapeutic proteins the Russian government reimburses.
Roman Ivanov, the R&D vice-president of Biocad, said: "Interferon beta-1a biosimilar is Biocad's third authorized medicine for treatment of RRMS, which makes our biotechnological company the only manufacturer of both APIs and drug products for all first generation disease-modifying therapies. Moreover, five other drugs for use in MS, including two novel molecules, are in different development phases, supplementing the Biocad’s autoimmune diseases pipeline."
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance